Pivotal-trial ARR Data

Phase 3 study results: Respectively for each trial, results for the primary end point vs teriflunomide: reduction of ARR: 51% (0.11 vs 0.22), 58% (0.10 vs 0.25); for the key secondary end points vs teriflunomide: reduction of number of Gd+ T1 lesions per scan: 98% (0.01 vs 0.46), 94% (0.03 vs 0.52); reduction of annualized rate of NE T2 lesions: 82% (0.72 vs 4.00), 85% (0.64 vs 4.16); 3-month CDP risk reduction of 34% (10.9 vs 15.0).¹ 

ASCLEPIOS I & II study design: ASCLEPIOS I and II were 2 identical, randomized, active-controlled, double-blind Phase 3 studies in patients with relapsing MS, approximately 40% of whom were DMT treatment naïve. Patients were randomized to double-dummy SC KESIMPTA (20 mg every 4 weeks) or oral Aubagio^® (teriflunomide) (14 mg daily) for up to 30 months. Primary end point was ARR. Key secondary end points were number of Gd+ T1 lesions and annualized rate of NE T2 lesions, and reduction in risk of 3-month CDP. Treatment duration was variable based on end-of-study criteria. Maximum duration: 120 weeks; median duration: 85 weeks.¹

Treatment-naïve ARR Data

ARR reductions in recently diagnosed treatment-naïve patients on first-line KESIMPTA vs Aubagio

Primary end point: relative reduction in annualized relapses vs Aubagio²

This post hoc study assessed the benefit–risk profile of KESIMPTA vs Aubagio, comprising clinical and MRI data in a subpopulation of recently diagnosed treatment-naïve patients from the combined ASCLEPIOS I and II trial populations.²

Post hoc study design: Efficacy and safety data were drawn from the pooled ASCLEPIOS subpopulation of protocol-defined treatment-naïve patients who were within 0.1–2.9 years from diagnosis (median 0.35 and 0.36 years for KESIMPTA and Aubagio patients, respectively). Of the 1882 patients randomly assigned to treatment in ASCLEPIOS I and II, 615 (32.7%) were both recently diagnosed and treatment naïve at baseline (KESIMPTA: 314; Aubagio: 301).²
No conclusions can be drawn.

Open-label Extension Study ARR Data

74% risk reduction in ARR up to year 7 in patients who switched from Aubagio to KESIMPTA³

Limitations: This analysis represents chance findings. The open-label extension study is not blinded, not controlled, and includes inherent self-selection bias for remaining in the trial. This study is an ongoing trial and the data presented are an interim analysis. No conclusions of statistical or clinical significance can be drawn.

ALITHIOS study design: ALITHIOS is an open-label, umbrella extension, Phase 3b, single-arm study evaluating long-term (up to 7 years) data. The primary objective was to assess safety and tolerability (N=1969) in patients with RMS who had at least 1 dose of KESIMPTA (20mg SC) (including drop outs) from the ASCLEPIOS I/II, APLIOS, and APOLITOS trials. APLIOS (N=284) was a phase 2,12-week, open-label, parallel-group study. APOLITOS (N=62) is a phase 2, 24-week, double blind, placebo-controlled, parallel-group core-part followed by an open-label extension-part for up to 48 weeks, study in Japan and Russia. The secondary objective was to assess efficacy (N=1367) in patients with RMS who had at least 1 dose of KESIMPTA (20mg SC) from the ASCLEPIOS I and II trials who continued or switched to KESIMPTA treatment. A long-term (up to 7 years) analysis (n=465) was conducted to evaluate efficacy in the recently diagnosed treatment-naïve subgroup treated with KESIMPTA.^4-9

*Treatment-naïve was defined as patients not on any treatment prior to starting the clinical trials. This includes patients who started on KESIMPTA and patients who switched from Aubagio to KESIMPTA.¹⁰

Pivotal-trial MRI Data

Treatment-naïve MRI Activity Data

MRI lesion activity in recently diagnosed treatment-naïve patients on first-line KESIMPTA vs Aubagio²

This post hoc study assessed the benefit–risk profile of KESIMPTA vs Aubagio, comprising clinical and MRI data in a subpopulation of recently diagnosed treatment-naïve patients from the combined ASCLEPIOS I and II trial populations.²

Post hoc study design: Efficacy and safety data were drawn from the pooled ASCLEPIOS subpopulation of protocol-defined treatment-naïve patients who were within 0.1–2.9 years from diagnosis (median 0.35 and 0.36 years for KESIMPTA and Aubagio patients, respectively). Of the 1882 patients randomly assigned to treatment in ASCLEPIOS I and II, 615 (32.7%) were both recently diagnosed and treatment naïve at baseline (KESIMPTA: 314; Aubagio: 301).²

No conclusions can be drawn.

Open-label Extension Study MRI Data

98% risk reduction in Gd+ T1 lesions up to year 7 in patients who switched from Aubagio to KESIMPTA³

T1 Lesions Over Time¹²

T2 Lesions Over Time¹³

Limitations: This analysis represents chance findings. The open-label extension study is not blinded, not controlled, and includes inherent self-selection bias for remaining in the trial. This study is an ongoing trial and the data presented are an interim analysis. No conclusions of statistical or clinical significance can be drawn.

MRI activity with KESIMPTA in treatment-naïve patients up to 7 years⁴

Gd+ T1 lesions reductions up to 7 years⁴

NE T2 lesions reductions up to 7 years⁴

Limitations: This analysis represents chance findings. The open-label extension study is not blinded, not controlled, and includes inherent self-selection bias for remaining in the trial. This study is an ongoing trial and the data presented are an interim analysis. No conclusions of statistical or clinical significance can be drawn.

ALITHIOS study design: ALITHIOS is an open-label, umbrella extension, Phase 3b, single-arm study evaluating long-term (up to 7 years) data. The primary objective was to assess safety and tolerability (N=1969) in patients with RMS who had at least 1 dose of KESIMPTA (20mg SC) (including drop outs) from the ASCLEPIOS I/II, APLIOS, and APOLITOS trials. APLIOS (N=284) was a phase 2,12-week, open-label, parallel-group study. APOLITOS (N=62) is a phase 2, 24-week, double blind, placebo-controlled, parallel-group core-part followed by an open-label extension-part for up to 48 weeks, study in Japan and Russia. The secondary objective was to assess efficacy (N=1367) in patients with RMS who had at least 1 dose of KESIMPTA (20mg SC) from the ASCLEPIOS I and II trials who continued or switched to KESIMPTA treatment. A long-term (up to 7 years) analysis (n=465) was conducted to evaluate efficacy in the recently diagnosed treatment-naïve subgroup treated with KESIMPTA.^4-9

Real patient taking KESIMPTA who was compensated for time.
Individual results may vary.
No conclusions can be drawn.

*As evidenced by reduction in ARR, MRI (Gd+ T1 and T2 lesions), and 3- and 6-month CDP vs teriflunomide. Primary end point: ARR reduction of 51% (0.11 vs 0.22), 58% (0.10 vs 0.25).^1,11
†KESIMPTA Sensoready® Pens must be refrigerated at 2°C to 8°C (36°F to 46°F). Keep product in the original carton to protect from light until the time of use. Do not freeze. To avoid foaming, do not shake. If necessary, KESIMPTA may be stored at room temperature below 30°C (86°F) for up to 7 days and returned to the refrigerator, to be used within the next 7 days.¹

Full Study Population

KESIMPTA showed significant risk reduction in CDP vs Aubagio^1,11,14

Results from a prespecified meta-analysis of pooled data from ASCLEPIOS I and II^1,11,14

In the extension study, at 7 years

• Cumulative 3-month disability progression: KESIMPTA initiators, 26.3%; Aubagio to KESIMPTA switch, 29.8%¹⁵

• Cumulative 6-month disability progression: KESIMPTA initiators, 22.7%; Aubagio to KESIMPTA switch, 26.2%¹⁶

Limitations: This analysis represents chance findings. The open-label extension study is not blinded, not controlled, and includes inherit self-selection bias for remaining in the trial. This study is an ongoing trial and the data presented are an interim analysis. No conclusions of statistical or clinical significance can be drawn.

Treatment-naïve CDP Data at Year 7

28% risk reduction in 6-month cumulative disability progression (CDP) at year 7 with KESIMPTA first line vs later switch¹⁷

6-month CDP in first-line subgroup vs later switch*

This post hoc study assessed the benefit–risk profile of KESIMPTA vs Aubagio, comprising clinical and MRI data in a subpopulation of recently diagnosed treatment-naïve patients from the combined ASCLEPIOS I and II trial populations.²

Limitations: This analysis represents chance findings. The open-label extension study is not blinded, not controlled, and includes inherent self-selection bias for remaining in the trial. This study is an ongoing trial and the data presented are an interim analysis.² No conclusions of statistical or clinical significance can be drawn.

Post hoc extension study design: Efficacy and safety data were drawn from the pooled ASCLEPIOS subpopulation of protocol-defined treatment-naïve patients who were within 0.1–2.9 years from diagnosis (median 0.35 and 0.36 years for KESIMPTA and Aubagio patients, respectively). Of the 1882 patients randomly assigned to treatment in ASCLEPIOS I and II, 615 (32.7%) were both recently diagnosed and treatment naïve at baseline (KESIMPTA, 314; Aubagio, 301). 465 recently diagnosed and treatment-naïve patients entered the ALITHIOS trial, and 366/465 (78.7%) of treatment-naïve patients were still receiving KESIMPTA at the 7-year data cutoff (September 25, 2024).^2,17 No conclusions can be drawn.

ALITHIOS study design: ALITHIOS is an open-label, umbrella extension, Phase 3b, single-arm study evaluating long-term (up to 7 years) data. The primary objective was to assess safety and tolerability (N=1969) in patients with RMS who had at least 1 dose of KESIMPTA (20mg SC) (including drop outs) from the ASCLEPIOS I/II, APLIOS, and APOLITOS trials. APLIOS (N=284) was a phase 2,12-week, open-label, parallel-group study. APOLITOS (N=62) is a phase 2, 24-week, double blind, placebo-controlled, parallel-group core-part followed by an open-label extension-part for up to 48 weeks, study in Japan and Russia. The secondary objective was to assess efficacy (N=1367) in patients with RMS who had at least 1 dose of KESIMPTA (20mg SC) from the ASCLEPIOS I and II trials who continued or switched to KESIMPTA treatment. A long-term (up to 7 years) analysis (n=465) was conducted to evaluate efficacy in the recently diagnosed treatment-naïve subgroup treated with KESIMPTA.^4-9

NEDA-3 Full Study Population

No evidence of disease activity (NEDA-3) for 95% of patients at year 7^6,18

No evidence of disease activity (NEDA-3) for ~96% of treatment-naïve patients at year 7^4,18

Re-baselining for year 2 (months 12-24) was conducted at month 12 to adjust for impact of disease activity prior to treatment initiation (T2 lesions) and continuing through the first year of treatment. This re-baselining allows for the accurate measure of the disease activity as measured in year 2.^19,20

NEDA-3 post hoc analysis limitations: This analysis considers patients without evidence of disease activity (which may also include patients with partially missing information) as NEDA-3. A sensitivity analysis was conducted for the population of patients who completed the full 24 months of treatment.¹⁹ No conclusions of clinical outcomes can be drawn.

NEDA-3 post hoc analysis design: All patients from the pivotal trials, full analysis set population (all randomized patients with assigned treatments) who also received KESIMPTA in the ALITHIOS extension study (data cutoff: September 25, 2024) were included in the intent-to-treat principle except for patients who had reached NEDA-3 but discontinued from the study drug prematurely for reasons other than “lack of efficacy” or “death.” The outcomes presented here are the proportion of study patients within a treatment group who met the NEDA-3 criteria vs those who did not. The proportion of patients meeting NEDA-3 criteria was analyzed cross sectionally in 1-year time intervals across 7 years. Within the prespecified time period, patients who achieved NEDA-3 experienced no 6-month CDP; no confirmed relapse; no Gd+ T1 lesions; no NE T2 lesions; and no discontinuation from the study drug due to either lack of efficacy or death.^4,19
 

Real patient taking KESIMPTA who was compensated for time.
Individual results may vary.